An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.

Also called NCT02561078

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 420 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02561078
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02561078. Randomized; no masking; primary purpose treatment. Start 2015-10-20 (actual); primary completion 2017-05-09 (actual). Results posted on 2020-05-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
Acronym
VIVID
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Human regular U-500 insulin (CSII)
Intervention (Drug)
Human regular U-500 insulin (MDI)
Lead sponsor
Eli Lilly and Company (class: industry)
Collaborator
Insulet Corporation (class: industry)

Record details

Record id
cardio:ct-nct02561078
Content hash
d20983228bc8b8a798640b3ddadf340a28abfb61750a6262c9eebf17de85a1c3